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Symptoms of attention-deficit/hyperactivity disorder (ADHD) and psychosis risk share 
features which might represent an early vulnerability marker for schizophrenia. Early 
detection of individuals with this symptomatic overlap is relevant and may assist clini-
cians in their decision making for diagnosis and treatment. This study sought to analyze 
the capability of different instruments in the screening of patients for ADHD symptoms 
or at psychosis risk, assess their classification accuracy, and describe the extent 
of symptoms overlap between them. 243 adult patients completed one instrument 
screening for ADHD and two instruments screening for psychosis risk symptoms [Adult 
ADHD Self-Report Scale Symptom Checklist (ASRS-v1.1); Prodromal Questionnaire 
Brief Version (PQ-16); Self-Screen Prodrome (SPro)]. The ability of these instruments to 
distinguish between the symptomaticity of these patients appears modest. The most 
satisfactory scale to identify subjects at psychosis risk was SPro with its subscale 
psychosis risk. ASRS-v1.1 showed good reliability in assessing individuals as not 
having ADHD symptoms and had higher probability to achieve its own and the cut-
off of another questionnaire. Subjects having symptoms of psychosis risk and ADHD 
showed elevated symptomatology. Reliable instruments capable of separating ADHD 
symptoms from those of psychosis risk are needed to better identify the symptomatic 
overlap of this two conditions.
Keywords: attention-deficit/hyperactivity disorder, psychosis risk, prodrome, schizophrenia, screening
inTrODUcTiOn
Attention-deficit/hyperactivity disorder (ADHD) and schizophrenia are two neurodevelopmental 
disorders associated with a certain symptomatic overlap (1). Common features of both conditions 
are attentional difficulties, inner tension, emotional dysregulation, and disorganized behavior (2–6). 
While these problems are part of the symptoms of ADHD, they are more likely to arise at the level 
of associated features in schizophrenia (6). Neurocognitive and developmental deficits commonly 
precede schizophrenia (7), making it not only difficult to distinguish between the psychopathologies 
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of the two disorders but also to distinguish psychosis risk from 
ADHD symptoms. Studies on the clinical overlap of these con-
ditions or on the co-occurrence of ADHD and psychosis risk 
symptoms are relatively rare and inconsistent (5–7).
ADHD and schizophrenia are often accompanied by impair-
ment in major life activities (8–11). Therefore, early identifica-
tion of individuals with ADHD and those at risk of psychosis 
is imperative. The majority of individuals with a high risk of 
psychosis show ADHD symptoms (3, 5), which might be an 
early vulnerability marker for schizophrenia (12), especially 
also because individuals developing a schizophrenia spectrum 
disorder or children at genetic risk of schizophrenia have been 
more often diagnosed with an ADHD in childhood (12–14). 
Furthermore, a diagnosis of ADHD in childhood, compared 
to unipolar depression, was found to be most predictive of 
schizophrenia in adulthood (15). In their long-term prospective 
follow-up study, Dalsgaard et al. (16) showed that children and 
adolescents with a diagnosed ADHD were at a 4.3 times higher 
risk of developing schizophrenia in adulthood compared to 
controls.
In particular, executive function deficits (i.e., sustained atten-
tion, working memory, and vigilance) seem to reflect symptoms 
shared between psychosis risk and ADHD (3, 17), although 
findings of existing studies are inconsistent and difficult to 
compare. Attention deficits were frequently identified in subjects 
at psychosis risk symptoms (12, 17). However, it has also been 
reported that there are no significant differences in measures 
of cognitive function between individuals at psychosis risk and 
ADHD (18).
Hyperactivity and impulsivity, core symptoms of ADHD (19, 
20), are also observed in individuals at psychosis risk (7, 12, 21). 
Similar to ADHD patients (22), patients at psychosis risk show 
a progressively lower level of frustration tolerance and higher 
emotional lability (4, 17). In addition, individuals at psychosis 
risk have limited emotional regulation skills (4) similar to those 
of ADHD patients (22).
All these findings, although sparse and inconsistent, suggest 
that symptoms of ADHD, and psychosis risk share some common 
features. There is a need to better understand this overlap which 
may help clinicians in their decision-making for diagnosis and 
treatment.
Effective screening for ADHD and for symptoms of psychosis 
risk could reduce inadequate treatment prolonging the suffering 
of patients. Generally, the screening for a disorder is the first step 
of the diagnostic process (23, 24) with the aim of identifying 
individuals at high risk of a particular disease and patients already 
suffering from the disorder (25). An adequate screening instru-
ment should meet application-related, content, and methodical 
criteria. The screening process should be quick and easy to 
perform and allow an interpretation of the test results by means 
of cut-off values (COV) to separate healthy from clinical indi-
viduals. Screening tools satisfying these objectives are self-rating 
instruments addressing all relevant criteria of a specific disorder, 
and their efficacy and utility defined by several psychometric 
parameters: reliability, validity, sensitivity, and specificity.
Sensitivity (or true positive rate; SENS) refers to the prob-
ability of a positive test result being correctly identified in a 
person with a specific disorder. Specificity (or true negative rate; 
SPEC) measures the probability of a negative test result being 
correctly identified in a healthy person not suffering from a 
specific disorder (25). Two further parameters are relevant in 
this context: positive predictive value (PPV) and negative predic-
tive value (NPV). The first measures the level of probability at 
which individuals with a positive test value actually do suffer 
from a defined condition. The second measures the level of 
probability at which individuals with a negative test value do 
not actually suffer from a defined condition (25). A positive 
screening value does not, however, obviate the need for further 
diagnostic procedures but calls for a specific diagnostic pro-
cedure able to confirm or dismiss the suspicion of a particular 
disorder.
To further understand the potential overlap of ADHD and 
psychosis risk symptoms, the aim of this study was to analyze the 
capability of three different screening instruments in identifying 
patients at psychosis risk or with ADHD symptomatology and 
specify the classification accuracy of these instruments. A second 
analysis focused on the similarity of criteria present in these 
instruments, i.e., two screenings for psychosis risk symptoms 
[Prodromal Questionnaire Brief Version (PQ-16) (26); Self-Screen 
Prodrome (Spro) (27)] and one screening for ADHD symptoms 
[Adult ADHD Self-Report Scale Symptom Checklist (ASRS-v1.1) 
(28, 29)]. A further objective was to estimate odds ratios (OR) for 
each instrument. We analyzed the OR to achieve the COV of each 
different scale and tested how strongly the presence or absence 
of psychosis risk and ADHD symptoms is associated with the 
presence or absence of ADHD and psychosis risk symptoms in a 
clinical population. We hypothesized:
 (1) that the overlap of the measured scales between the two 
psychosis risk screenings is greater than that between the 
ADHD instrument and the two psychosis screenings.
 (2) that a stronger association exists between the two instru-
ments screening for psychosis risk symptoms than between 
those two instruments and the one screening for ADHD.
 (3) that psychosis risk symptoms are not to distinguish from 
ADHD symptoms with reliable and valid instruments 
screening symptoms for psychosis risk or ADHD.
MaTerials anD MeThODs
Participants
The sample included a total of 243 patients recruited across eight 
(mainly outpatient) clinics that belonging to the University of Basel 
Psychiatric Clinics (UPC) in Basel (Switzerland) between March 
2013 and August 2014. Participants gave written informed con-
sent. The study was formally approved by the Ethics Committee of 
Basel (Ethikkommission Nordwest- und Zentralschweiz). There 
were 155 (63.8%) males and 88 (36.2%) females with a gender 
difference [χ2 (1, N = 243) = 18.47, p < 0.001]. Participating indi-
viduals were between 18 and 75 years old (M = 35.83, SD = 11.38) 
and being treated in one of the eight clinics at UPC with group 
differences in gender [χ2(7, N =  243) =  23.46, p =  0.001] and 
age [ANOVA: F(7, 243) = 8.86, p < 0.001]. The distribution of 
TaBle 1 | Distribution of the sample (N = 243) in gender and age in the different clinics.
clinics at University of Basel Psychiatric clinics (UPc)
Zaa ZDKb VTac FaMd aDse U3f Zassg ZFMh
n (%) 42 (17.3) 22 (9.1) 59 (24.3) 5 (2.1) 84 (34.6) 8 (3.3) 13 (5.3) 10 (4.1)
Genders
Female: n (%) 11 (12.5) 8 (9.1) 35 (39.8) 0 (0) 25 (28.4) 1 (1.1) 6 (6.8) 2 (2.3)
Male: n (%) 31 (20.0) 14 (9.0) 24 (15.5) 5 (3.2) 59 (38.1) 7 (4.5) 7 (4.5) 8 (5.2)
Age: M (SD) 34.36 (1.59) 26.59 (2.19) 31.76 (1.34) 34.00 (4.60) 42.20 (1.12) 38.63 (3.63) 34.92 (2.85) 32.70 (3.25)
aCentral Patient Admission [Zentrale Aufnahme].
bCenter for Diagnostic and Crisis Intervention [Zentrum für Diagnostik und Krisenintervention].
cAmbulance Behavioral Therapy [Verhaltenstherapie Ambulanz].
dForensic Ambulance [Forensische Ambulanz].
eAmbulance Addiction Services [Ambulanz für Sucht].
fInpatient Unit for Substance Dependence and Addiction [Stationäre Abteilung für Abhängigkeit und Sucht].
gCenter for Affective, Stress and Sleep Disorder [Zentrum für Affektive-, Stress- und Schlafstörungen].
hCenter for Psychotic Disorders and Transcultural Psychiatry [Zentrum für psychotische Erkrankungen und transkulturelle Psychiatrie].
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the sample as to gender and age across the different clinics is 
presented in Table 1.
Procedure
Three different self-rating scales assessing ADHD or psychotic 
symptoms were distributed mainly to outpatient clinics (seven 
outpatient, one inpatient) at UPC. The medical staff, primarily 
psychiatrists and psychologists, were briefed about the study 
and passed the questionnaires to participants during the 
process of admission in the different clinics. Details about the 
study, informed consent forms to be signed and instructions on 
how to complete the scales were given to participants in written 
form. The completed questionnaires were collected regularly, 
evaluated, and returned to the attending psychiatrists and 
psychologists. For patients who exceeded the COV, referral to 
our specialized ADHD or early detection of psychosis clinic was 
recommended.
instruments
Adult ADHD Self-Report Scale Symptom Checklist 
[ASRS-v1.1 (28, 29)]
The World Health Organization self-rating scale is based on 
the 18 DSM-IV ADHD criteria and may provide information 
suggesting the need of a more in-depth diagnostic evaluation. 
Six (part A) of the 18 questions were found the most predictive 
of symptoms consistent with ADHD in adulthood (29). The 12 
remaining questions (part B) provide additional cues on the 
patient’s symptoms. The instrument with its five-point scale 
from never (0) to very often (4) takes about 5 min to complete. 
The total score is calculated from the sum value of each item. 
The higher the score, the more pronounced the symptoms are. 
In addition to the sum score of the checklist, the scores for the 
two subscales inattention and hyperactivity/impulsivity can be 
calculated. Part A helps to identify patients’ symptoms correctly. 
Part B records the severity of the symptoms identified. Part 
A is seen as the short version of the checklist [ASRS-6 (29)], 
consisting of four items from the inattention and two from 
the hyperactivity/impulsivity subscale. By exceeding a cut-off 
value of 4 in ASRS-6, an adult ADHD is likely. Kessler et  al. 
(29) established good psychometric properties for the screener 
(ASRS-6) and the full version (ASRS-18): sensitivity: 68.7 
versus 56.3%, specificity: 99.5 versus 98.3%, total classification 
accuracy: 97.9 versus 96.2%, and Cohen’s κ: 0.76 versus 0.58. 
Buchli-Kammermann et al. (30) determined the psychometric 
quality of the German version, obtaining similar values for 
both versions (ASRS-6 versus ASRS-18): sensitivity: 66.6 versus 
72.3%; specificity: 64.9 versus 68.1%, Cronbach’s α: 0.73 versus 
0.89. For the screening process the ASRS-6 proved particularly 
relevant. Ramos-Quiroga et al. (31) revealed a new strategy in 
scoring symptoms by using a quantitative ranking between 0 
and 24 points for either subscale (inattention and hyperactivity/
impulsivity) with a cut-off value of 12 points (sensitivity: 96.7%, 
specificity: 91.1%, Cohen’s κ: 0.88). For the current study, the 
short (ASRS-6) and full version (ASRS-18) of this screening 
instrument were used. The cut-off value of 12 points in the full 
version (ASRS-18) proposed by Ramos-Quiroga et al. (31) was 
adopted.
Prodromal Questionnaire Brief Version [PQ-16 (26)]
The self-rating scale is a brief version of the Prodromal 
Questionnaire with 92 items (32) able to identify subjects at 
psychosis risk on a two-point scale (true/false). PQ-16 consists 
of three subscales: positive (perceptual abnormalities/hallucina-
tions; 9 items), disorganized (unusual thought content/delusional 
ideas/paranoia; 5 items), and negative symptoms (excessive social 
anxiety/avolition; 2 items). A COV of ≥6 has high sensitivity 
(87%) and high specificity (87%) with a PPV of 44%, and an 
internal consistency of Cronbach’s α 0.774.
Self-Screen Prodrome [Spro (27)]
This self-rating scale differentiates between healthy individuals, 
individuals with psychosis or at psychosis risk, and patients 
with other mental disorders. It has 32 items on a two-point scale 
(true/false): items 1–24 measure psychopathological changes with 
nonspecific, negative and positive symptoms of a psychosis; 
items 25–29 determine the level of psychosocial functioning; items 
30–32 detect psychosis risk deriving from a genetic vulnerability or 
consumption of substances. Six items frame the subscale psychosis 
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risk and are seen as decisive prodromal symptoms. If at least two 
items are answered positively, an in-depth diagnostic procedure 
in a special consultation for the early detection of psychoses is 
recommended.
An SPro total score of ≥6 indicates the presence of a mental 
disorder with a sensitivity of 85% and a specificity of 91%. A psy-
chosis risk subscale score ≥2 distinguishes between psychosis-
(risk)-individuals and outpatients with another mental disorder 
with a sensitivity of 85% and a specificity of 39%. The internal 
consistency of the scale for healthy individuals (Cronbach’s 
α = 0.75), psychosis-(risk)-individuals (Cronbach’s α = 0.89), and 
individuals with another mental disease (Cronbach’s α = 0.89) is 
acceptable. In particular, the sum score and the subscale psychosis 
risk of this instrument were taken into consideration.
Data analysis
Data analyses were conducted using SPSS Version 23. First, the 
sample was described regarding probable differences in gender, 
age, clinics, and the four diagnostic category groups: (01) no indi-
cation of symptoms; (02) indication of ADHD symptoms; (03) 
indication of psychosis symptoms; and (04) indications of ADHD 
and psychosis symptoms. To analyze a potential symptoms overlap 
several χ2-tests identified the number of cases (individuals under 
or above the COV) detected by the three instruments used. The 
internal consistency for all scales was estimated with Cronbach’s α, 
the relationship between them with Spearman’s correlation 
coefficients. Analyses of the Receiver Operating Characteristics 
(ROC) were performed to examine SENS, SPEC, PPV, NPV, and 
the area under the curve (AUC). The ROC curve analysis is used 
to compare the diagnostic performance of the different screen-
ing instruments. The AUC measures the discrimination, i.e., the 
ability of an instrument to correctly classify individuals with and 
without ADHD or psychotic risk symptoms. The OR to achieve 
not only the COV of one instrument but also that of another were 
analyzed with χ2-tests. The characteristics of the symptoms over-
lap of the different instruments in the four diagnostic category 
groups were visualized with exploratory data analysis.
resUlTs
Descriptive statistics
The analyses of the questionnaires showed that 35.8% (n = 87) of 
the sample had no symptoms of psychosis risk or ADHD, 3.3% 
(n = 8) presented with ADHD and 40.7% (n = 99) with psycho-
sis risk symptoms only; 20.2% (n = 49) displayed symptoms of 
ADHD as well as psychosis risk symptoms. The comparisons 
between the four established diagnostic categories were statisti-
cally not significant in gender [χ2(3, N = 243) = 2.44, p = 0.49], 
age [ANOVA: F(3, 243) =  0.89, p =  0.447], and clinics [χ2(21, 
N = 243) = 27.34, p = 0.16].
Differences in Frequency of cases below 
or above the cOV of asrs-v1.1, sPro,  
and PQ-16
To better understand the relationship between the instruments 
(subscales and sum scales) used, different χ2-tests were conducted 
(Table  2). All comparisons were statistically significant except 
that between ASRS-18 and SPro. The observed frequencies of 
individuals achieving or exceeding the COV were nearly all 
statistically significantly higher than the expected frequencies, 
as were the observed frequencies of individuals not achieving or 
exceeding the COV. The short version of the ASRS-v1.1 (ASRS-6) 
shared one of the highest frequencies with the other subscales and 
sum scales. The observed frequencies of individuals achieving or 
exceeding the COV in ASRS-6 and in the SPro subscale psychosis 
risk (n = 71, 30.3%) and SPro (n = 69, 29.5%) were most prevalent.
internal consistency, convergent, and 
Divergent Validity of asrs-v1.1, sPro,  
and PQ-16
The internal consistency was estimated for all scales. SPro showed 
the highest with a Cronbach’s α of 0.959, succeeded by ASRS-18 
(α = 0.898), ASRS-18 inattention (α = 0.847), ASRS-18 hyperac-
tivity/impulsivity (α = 0.841), PQ-16 (α = 0.826), SPro psychosis 
risk (α = 0.800), and ASRS-6 (α = 0.702).
The correlations of the total scores are presented in Table 3 
with instruments correlating significantly (p  <  0.01) among 
themselves. As expected, the correlations between scales 
measuring similar aspects {e.g., SPro versus SPro psychosis risk 
[rs(234) =  0.826] or PQ-16 [rs(232) =  0.600]} were strong. By 
contrast, ASRS-18 versus SPro psychosis risk or SPro, measuring 
different areas of symptomaticity, showed a small correlation only 
[rs(233) = 0.380 and rs(234) = 0.474].
receiver Operating characteristics 
analyses of asrs-v1.1, sPro, and PQ-16
The sum score of every scale was compared with the COV of the 
subscales and sum scales of the instruments used. The results are 
shown in Table 4. The AUC was significant in the comparisons of all 
scales. The highest SENS was exemplified by the sum scale of SPro 
and its subscale psychosis risk, which was found to be the best scale to 
identify individuals at risk of symptoms of psychosis. The ASRS-v1.1 
(ASRS-18) had the highest values of SPEC, indicating the capacity to 
detect correctly individuals not having symptoms of ADHD.
Odds ratios: achievement of Different 
cOV of asrs-v1.1, sPro, and PQ-16
The association between the COV of the different scales was 
represented with OR. The aim was to estimate the OR to achieve 
the COV of one scale in relation to the achievement of the COV 
of another scale. These results are introduced in Table  5. The 
ASRS-18, in comparison to its short form ASRS-6, had a higher 
probability of achieving the COV of another instrument: The 
probability for the COV of the ASRS-18 to achieve the COV of 
SPro subscale psychosis risk has an OR of 6.059, and an OR of 
4.696 for the achievement of the COV of the PQ-16.
exploratory Data analysis: symptoms 
Overlap of asrs-v1.1, sPro, and PQ-16
The means of the total score of the different measures were analyzed 
and compared in the four diagnostic groups: (01) no indication of 
symptoms; (02) indication of ADHD symptoms; (03) indication of 
TaBle 2 | Number of cases below or above the cut-off value (COV) of the different scales.
scale asrs-18 sPro psychosis risk sPro PQ-16e
cOVf < 12 cOV ≥ 12 cOV < 2 cOV ≥ 2 cOV < 6 cOV ≥ 6 cOV < 6 cOV ≥ 6
ASRS-6a COV < 4 Count 155 4 62 93 37 118 130 28
Expected count 132.7 26.3 46.4 108.6 31.1 123.9 117.8 40.2
% of Total 64.0 1.7 26.5 39.7 15.8 50.4 54.2 11.7
COV ≥ 4 Count 47 36 8 71 10 69 49 33
Expected count 69.3 13.7 23.6 55.4 15.9 63.1 61.2 20.8
% of Total 19.4 14.9 3.4 30.3 4.3 29.5 20.4 13.8
ASRS-18b COV < 12 Count 67 129 43 153 161 40
Expected count 58.6 137.4 39.4 156.6 149.9 51.1
% of Total 28.2 55.1 18.4 65.4 67.1 16.7
COV ≥ 12 Count 3 35 4 34 18 21
Expected count 11.4 26.6 7.6 30.4 29.1 9.9
% of Total 1.3 15.0 1.7 14.5 7.5 8.8
SProc psychosis risk COV < 2 Count 37 33 64 5
Expected count 14.0 56.0 51.5 17.5
% of Total 15.7 14.0 27.6 2.2
COV ≥ 2 Count 10 155 109 54
Expected count 33.0 132.0 121.5 41.5
% of Total 4.3 66.0 47.0 23.3
SProd COV < 6 Count 44 2
Expected count 34.3 11.7
% of Total 19.0 0.9
COV ≥ 6 Count 129 57
Expected count 138.7 47.3
% of Total 55.6 24.6
aAdult attention-deficit/hyperactivity disorder (ADHD) Self-Report Scale Symptom Checklist: part A (6 items).
bAdult ADHD Self-Report Scale Symptom Checklist: parts A & B (18 items).
cSelf-Screen Prodrome: subscale psychosis risk.
dSelf-Screen Prodrome.
eProdromal Questionnaire Brief Version.
fCut-off value.
χ2ASRS-6 – ASRS-18 (1, N = 242) = 65.982, p < 0.001.
χ2ASRS-6 – SPro psychosis risk (1, N = 234) = 22.274, p < 0.001.
χ2ASRS-6 – SPro (1, N = 234) = 4.099, p < 0.05.
χ2ASRS-6 – PQ-16 (1, N = 240) = 14.445, p < 0.001.
χ2ASRS-18 – SPro psychosis risk (1, N = 234) = 10.492, p = 0.001.
χ2ASRS-18 – SPro (1, N = 234) = 2.583, p = 0.108.
χ2ASRS-18 – PQ-16 (1, N = 240) = 19.854, p < 0.001.
χ2SPro psychosis risk – SPro (1, N = 235) = 67.270, p < 0.001.
χ2SPro psychosis risk – PQ-16 (1, N = 232) = 17.125, p < 0.001.
χ2SPro – PQ-16 (1, N = 232) = 13.449, p < 0.001.
TaBle 3 | Spearman correlations of the total score of the different scales.
scale asrs-6 asrs-18 sPro 
psychosis 
risk
sPro PQ-16e
ASRS-6a 0.835** 0.380** 0.474** 0.421**
ASRS-18b 0.499** 0.604** 0.526**
SProc psychosis risk 0.826** 0.536**
SProd 0.600**
aAdult attention-deficit/hyperactivity disorder (ADHD) Self-Report Scale Symptom 
Checklist: part A (6 items).
bAdult ADHD Self-Report Scale Symptom Checklist: parts A & B (18 items).
cSelf-Screen Prodrome: subscale psychosis risk.
dSelf-Screen Prodrome.
eProdromal Questionnaire Brief Version.
**p < 0.01.
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psychosis symptoms; and (04) indications of ADHD and psychosis 
symptoms. Individuals with ADHD as well as psychosis symptoms 
had higher means in nearly every instrument. Only in the ASRS-6 
did subjects with an indication of ADHD symptoms achieve a 
slightly higher mean (cf. Figure 1). The analyses of the ASRS-18 
subscales of inattention and hyperactivity/impulsivity, presented 
in Figure  2, showed higher means for the diagnostic group (4) 
(subjects with ADHD and psychosis symptoms).
DiscUssiOn
The current study analyzes the ability of three different instru-
ments to screen patients at risk of psychosis or ADHD and 
the symptomatic overlap measured with these questionnaires. 
TaBle 5 | Odds ratios (OR) to achieve the cut-off values (COV) of different scales.
scale asrs-18 sPro psychosis 
risk
sPro PQ-16e
ASRS-6a ORf 29.681 5.917 2.164 3.127
95% CIg
Lower 10.046 2.663 1.013 1.714
Upper 87.692 13.148 4.622 5.705
ASRS-18b OR 6.059 2.389 4.696
95% CI
Lower 1.797 0.803 2.289
Upper 20.432 7.104 9.633
SProc psychosis 
risk
OR 17.379 6.341
95% CI
Lower 7.862 2.412
Upper 38.415 16.674
SProd OR 9.9721
95% CI
Lower 2.278
Upper 41.480
aAdult attention-deficit/hyperactivity disorder (ADHD) Self-Report Scale Symptom 
Checklist: part A (6 items).
bAdult ADHD Self-Report Scale Symptom Checklist: parts A & B (18 items).
cSelf-Screen Prodrome: subscale psychosis risk.
dSelf-Screen Prodrome.
eProdromal Questionnaire Brief Version.
fOdds ratio.
gConfidence interval.
TaBle 4 | Classification accuracy of the different scales, i.e., sensitivity (SENS), 
specificity (SPEC), positive predictive value (PPV), negative predictive value 
(NPV), area under the curve (AUC), and confidence interval (CI).
sensa sPecb PPVc nPVd aUce cif
asrs-6g
ASRS-18h 90.00 76.73 43.37 97.48 0.923*** 0.886–0.959
SPro psychosis 
riski
43.29 88.57 89.87 40.00 0.746*** 0.679–0.813
SProj 36.90 78.72 87.34 23.87 0.690*** 0.599–0.782
PQ-16k 54.10 72.62 40.24 82.28 0.721*** 0.649–0.793
asrs-18
ASRS-6 43.37 97.48 90.00 76.73 0.906*** 0.870–0.943
SPro psychosis 
risk
21.34 95.71 92.11 34.18 0.793*** 0.731–0.854
SPro 18.18 91.49 89.47 21.94 0.749*** 0.665–0.833
PQ-16 34.43 89.94 53.85 80.10 0.749*** 0.679–0.819
sPro psychosis risk
ASRS-6 89.87 40.00 43.29 88.57 0.671*** 0.600–0.742
ASRS-18 92.11 34.18 21.34 95.71 0.694*** 0.597–0.790
SPro 82.45 78.72 93.94 52.86 0.839*** 0.777–0.902
PQ-16 91.53 36.99 33.13 92.75 0.746*** 0.671–0.821
sPro
ASRS-6 87.34 23.87 36.90 78.72 0.709*** 0.641–0.778
ASRS-18 89.47 21.94 18.18 91.49 0.739*** 0.644–0.834
SPro psychosis 
risk
93.94 52.86 82.45 78.72 0.851*** 0.797–0.905
PQ-16 96.61 25.43 30.65 95.65 0.763*** 0.693–0.832
PQ-16
ASRS-6 40.24 82.28 54.10 72.62 0.683*** 0.612–0.753
ASRS-18 53.85 80.10 34.43 89.94 0.773*** 0.694–0.852
SPro psychosis 
risk
33.13 92.75 91.53 36.99 0.722*** 0.654–0.790
SPro 30.65 95.65 96.61 25.43 0.736*** 0.660–0.811
aSensitivity.
bSpecificity.
cPositive predictive value.
dNegative predictive value.
eArea under the curve.
fConfidence interval.
gAdult attention-deficit/hyperactivity disorder (ADHD) Self-Report  
Scale Symptom Checklist: part A (6 items).
hAdult ADHD Self-Report Scale Symptom Checklist:  
parts A & B (18 items).
iSelf-Screen Prodrome: subscale psychosis risk.
jSelf-Screen Prodrome.
kProdromal Questionnaire Brief Version.
***p > 0.001.
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Overall, the ability of ASRS-v1.1, SPro, and PQ-16 to dis-
tinguish clearly between patients with these symptoms is 
found to be modest. The most satisfactory scale to identify 
subjects with a risk of psychosis was SPro and its subscale 
psychosis risk. ASRS-18 showed good ability to detect correctly 
individuals not presenting with symptoms of ADHD. However, 
this instrument demonstrated a higher probability to achieve, 
besides its own COV, the COV of another questionnaire. 
Individuals showing symptoms of psychosis as well as ADHD 
had elevated symptomatology in nearly all instruments. With 
the instruments analyzed here, it appears difficult in a clinical 
sample to differentiate clearly between ADHD and psychotic 
symptoms.
The biggest overlap between individuals achieving the COV of 
two different questionnaires was not found, as expected, between 
scales defining similar aspects but between the SPro subscale 
psychosis risk and ASRS-6, which proved to be even higher than 
that found between ASRS-6 and ASRS-18. Marwaha et  al. (7) 
demonstrated a similar association between ADHD and psychosis 
with a higher score of ASRS-6 being significantly associated with 
psychosis. Overall, ASRS-6 shared the highest case frequencies 
with the other scales. The overlap between PQ-16 and both ver-
sions of ASRS-v1.1 was, however, as expected, the smallest. SPro 
and ASRS-v1.1 seem to share many more aspects of psychotic 
and ADHD symptoms than PQ-16 and ASRS-v1.1: while in SPro 
symptoms defining disturbance of attention, hyperactivity, and 
impulsivity, but also of emotional dysregulation, are frequent and 
similar to items in ASRS-v1.1, the items of PQ-16 center more on 
symptoms of delusions and boundary disturbances.
The internal consistency reflecting the homogeneity of the 
scales was for nearly all instruments moderate to high, with only 
ASRS-6 having a small Cronbach’s α. In comparison, ASRS-18 
showed a high internal consistency. These results are similar to 
of Buchli-Kammermann et al. (30). SPro had the highest internal 
consistency of all instruments, exceeding Kammermann et  al.’s 
(27) estimate.
All correlations between the total scores of the instruments 
were statistically significant. As expected, the correlations of 
scales defining similar constructs were all in all stronger than 
those defining different constructs. However, these correlations 
were only slightly stronger, raising the question whether these 
scales are not to unspecific to distinguish between ADHD and 
psychosis risk symptoms. The correlation of SPro psychosis risk 
FigUre 1 | Symptomatic overlap between the four diagnostic groups: 
means of the total score of 01Adult attention-deficit/hyperactivity disorder 
(ADHD) Self-Report Scale Symptom Checklist: part A (6 items); 02Adult ADHD 
Self-Report Scale Symptom Checklist: parts A & B (18 items); 03Self-Screen 
Prodrome: subscale psychosis risk; 04Self-Screen Prodrome; 05Prodromal 
Questionnaire Brief Version.
FigUre 2 | Symptomatic overlap between the four diagnostic groups: 
means of the total score of 01Adult attention-deficit/hyperactivity disorder 
(ADHD) Self-Report Scale Symptom Checklist: subscale inattention; 02Adult 
ADHD Self-Report Scale Symptom Checklist: subscale hyperactivity/
impulsivity.
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and ASRS-18 were strong, although these scales define two dif-
ferent construct. The correlations between ASRS-6 and ASRS-18, 
between SPro psychosis risk and SPro were strong as well because 
they share some identical items. The convergent and the divergent 
validity are at the end not satisfying.
The balance of the SENS, SPEC, PPV, and NPV in the ROC 
analyses was modest. The purpose of a screening instrument is 
to identify as many individuals as possible with a specific set 
of symptoms, i.e., the SENS of a screening instrument should 
preferably be high compared to the SPEC. Only the SPro and its 
subscale psychosis risk meet this requirement. The SENS of the 
other instruments was mostly higher than the SPEC, indicating 
they were better able to correctly identify subjects presenting 
with neither psychotic nor ADHD symptoms. Nonetheless, the 
AUC values discriminating between positive and negative cases 
were statistically significant in all comparisons, centering around 
0.7, with a value of 0.5 indicating no difference, and 1.0 a perfect 
separation of two specific groups.
Compared to ASRS-6, ASRS-18 showed the highest OR 
to achieve its own COV and that of an instrument measuring 
psychosis risk symptoms. Consequently, the symptomatic overlap 
between ASRS-18 and the SPro subscale psychosis risk seems the 
most important, indicating that ASRS-6 is better able to detect 
individuals with ADHD symptoms and to be preferred. As to 
psychotic symptoms, SPro had the smallest OR and is to be pre-
ferred for identifying subjects at risk of psychosis. The OR results 
for instruments defining similar constructs were as expected: 
the probability for an instrument to achieve the COV of another 
questionnaire was higher for scales determining similar rather 
than different aspects.
The analyses of the four diagnostic groups showed patients 
with ADHD as well as psychotic symptoms had a higher symp-
tomatic overlap than the others, both in the sum and sub scores. 
Subjects with either ADHD or psychotic symptoms were not 
better identified with the specific questionnaires.
Although the instruments used were all found reliable and 
valid in previous studies analyzing their psychometric properties 
(26–29), they are shown here not to be reliable enough to separate 
symptoms of ADHD from those of psychosis risk. The purpose 
of a screening instrument is to filter out patients with suspicious 
symptoms and to initiate timely and appropriate diagnostic 
procedures and interventions. Unfortunately, the present results 
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fail to clarify which instruments are better able to identify patients 
with ADHD or psychosis risk symptoms. The reason might lie 
in the difficulty to distinguish between the—to some extent 
nonspecific—symptoms of these two conditions and in the 
complexity of symptoms of both ADHD and psychosis risk (33). 
Consistent with other studies (2, 3, 7, 17), this study confirms the 
overlap between ADHD and psychosis risk symptoms possibly 
reflecting similar characteristics between ADHD and psychosis 
risk [environmental risk factors and neurobiological substrates 
(3)]. The aim of a systematic screening process is to allow the 
identification of risk patients, here also to prevent or delay transi-
tion to psychoses and so improve prognosis and save treatment 
costs (34). The evident symptomatic overlap makes it difficult to 
refer patients to a special consultation unit for a specific diagnostic 
procedure allowing for suspected ADHD or psychoses either to 
be confirmed or dismissed. This underlines the need for sensitive 
screening instruments in this specific field.
limitations
There are several limitations to these findings. The use of self-rating 
scales only could be problematic for both patients experiencing 
symptoms of psychosis risk (35) and individuals with ADHD 
symptoms (36). Additional observer-rating scales could help to 
better understand the symptomatic overlap between ADHD and 
psychosis risk and enable the comparison of results from different 
sources of information. Another possible weakness of the study 
is the small number of patients presenting with an indication of 
ADHD only. This may lead to an inflation of the present results, 
giving individuals with only psychosis risk symptoms or with 
ADHD and psychosis risk symptoms more weight in the statisti-
cal analyses.
It will be important to replicate the present study by extending 
the method of assessing ADHD and psychosis risk symptoms in 
a randomized, controlled trial. The assessment and analysis of 
other psychiatric and comorbid disorders of the participants is 
to consider and is highly recommendable, in order to make more 
accurate statements. Finally, it is questionable whether the COV 
proposed by Ramos-Quiroga et al. (31) and adopted in this study 
is also valid in a German-speaking sample.
cOnclUsiOn
To the best of our knowledge, the present study is the first to 
analyze the ability of ASRS-v1.1, SPro, and PQ-16 in a het-
erogeneous adult population seeking psychiatric treatment. 
The ability of the three different instruments to distinguish 
between patients at risk of ADHD or psychosis is found to be 
modest. The symptomatic overlap between these two conditions 
evidently makes it difficult to identify either disorder correctly 
and to give definitive advice on initiating specific diagnostic 
procedures. There is a need for reliable and sensitive screening 
instruments able to clearly separate symptoms of ADHD from 
those of psychosis to prevent further suffering and impairments 
in major life activities for patients at risk of these conditions and 
to reduce treatment costs.
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